Core Cap Advisors, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Core Cap Advisors, LLC
- $2.07 Billion
- Q3 2024
A detailed history of Core Cap Advisors, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 400 shares of CPRX stock, worth $7,812. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400
Previous 400
-0.0%
Holding current value
$7,812
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CPRX
# of Institutions
325Shares Held
94.1MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$365 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$157 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$122 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$111 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$59 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.01B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...